Haleon (LON:HLN) Releases Earnings Results

Haleon (LON:HLN) announced its quarterly earnings data on Thursday. The company reported GBX 8.60 earnings per share for the quarter, Digital Look Earnings reports. Haleon had a return on equity of 10.30% and a net margin of 15.11%.

Haleon Stock Down 1.4%

HLN stock opened at GBX 363.30 on Friday. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93. The firm has a market capitalization of £32.00 billion, a P/E ratio of 19.64, a P/E/G ratio of 1.49 and a beta of 0.24. Haleon has a 52-week low of GBX 317.80 and a 52-week high of GBX 416.10. The company’s 50 day simple moving average is GBX 349.84 and its 200-day simple moving average is GBX 363.11.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HLN. Jefferies Financial Group restated a “buy” rating and set a GBX 400 price objective on shares of Haleon in a research report on Friday. Berenberg Bank reissued a “buy” rating and set a GBX 512 target price on shares of Haleon in a research note on Thursday, April 30th. JPMorgan Chase & Co. reduced their target price on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a report on Thursday, June 25th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Haleon from GBX 325 to GBX 335 and gave the stock a “sell” rating in a research report on Friday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 370 price target on shares of Haleon in a report on Thursday, April 30th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of GBX 395.33.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.